Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMT-676 in Advanced Colorectal Cancer
NCT07474727Phase 2Recruiting
- Sponsor
- Multitude Therapeutics
- Start
- Apr 2026
- Primary completion
- Sep 2027
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of AMT-676 in colorectal cancer (CRC), sponsored by Multitude Therapeutics. Started Apr 2026; status: recruiting.
02
Drugs
AMT-676
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07474727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07474727.